Cannabis-based products for medicinal use: call for evidence
Published 17 September 2025
© Crown copyright 2025
This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit nationalarchives.gov.uk/doc/open-government-licence/version/3 or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email: psi@nationalarchives.gov.uk.
Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.
This publication is available at https://www.gov.uk/government/calls-for-evidence/cannabis-based-products-for-medicinal-use/cannabis-based-products-for-medicinal-use-call-for-evidence
About this call for evidence
The Advisory Council on the Misuse of Drugs (ACMD) is reviewing the evidence on the impact of the 2018 changes to the Misuse of Drugs Regulations 2001 to include cannabis-based products for medicinal use (CBPMs). CBPMs are cannabis-based products for medicinal use in humans, that have not been assessed by the medicines regulator.
The report aims to consider the evidence to review if the legislation had the intended impact and identify any unintended consequences to offer recommendations on how to mitigate these.
We welcome submissions of evidence from as broad a spectrum of participants as possible and would be grateful if you could please circulate this call for evidence to other colleagues and relevant stakeholders.
The ACMD will use this evidence to assist in formulating advice to government.
How to respond
You can complete the questionnaire online or return the downloadable version to the ACMD Secretariat at: acmd@homeoffice.gov.uk
Please respond by 11:59 pm on Friday 17 October.
Although your expertise may be better suited to tackling only some of the questions, it would be helpful if you were to consider every question in the questionnaire.
If possible, please provide supporting evidence and references in your response.
How we will use your information
Respondents should note that evidence submitted will inform the development of recommendations from the ACMD and could ultimately be published.
However, in the interest of confidentiality and protecting commercial interests, any information submitted will be non-attributable.
All data submitted in response to this call for evidence will be protected by the ACMD Secretariat in accordance with the UK General Data Protection Regulation (UK GDPR).
Furthermore, Section 43(1) of the Freedom of Information Act provides an exemption for information which is a trade secret, whilst Section 43(2) exempts information whose disclosure would, or would be likely to, prejudice the commercial interests of any person (an individual, a company, the public authority itself or any other legal entity).